Clinical Trial Details

Toray TRY-003D – Analysis by EarlyGuard™ miRNA from Women Referred for Additional Testing Due to Abnormal Breast Imaging Classified as Bl-RADS® of 3, 4, or 5 (Toray TRY-003D)

This protocol describes a simple, non-significant risk (NSR) clinical study, in which a single 5.0 – 10.0 mL sample of whole blood is drawn from each enrolled Subject meeting requirements of one of the three Study arms.

Principal Investigator(s)

Suzanne Rose, PhD


Toray International America, Inc.


Hospitalist at 203-358-8879 or [email protected]


Bennett Cancer Center
One Hospital Plaza
Stamford, CT 06902
Main: 203-276-2695

Our website uses cookies

This website uses cookies to give you the very best experience. Your continued use of this site is considered permission by you to use cookies in this manner. Please review our Privacy Policy and Terms of Use for more information about the data we collect and the types of cookies we use. Please note, if you link off our website to a 3rd party site of any kind, that website has its own terms and conditions.